Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa use

besponsa use

Перейти к контенту

Главное меню:

Разное
besponsa use
Welcome to BESPONSA® | BESPONSA®, Besponsa: Uses, Side Effects, Benefits/Risks | Drugs.com, Besponsa - FDA prescribing information, side effects and uses, About BESPONSA® | BESPONSA®, BESPONSA 1 mg powder for concentrate for solution for , BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , Besponsa (inotuzumab ozogamicin) Side Effects , inotuzumab ozogamicin (Besponsa) - scottishmedicines.org.uk, FDA approves new treatment for adults with relapsed or .
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . INDICATION and IMPORTANT SAFETY INFORMATION. BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. Besponsa can only be obtained with a prescription, and treatment should be given under the supervision of a doctor who has experience in the use of cancer treatments. For further information, see the package leaflet..
Besponsa is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 2. DOSAGE AND ADMINISTRATION. Males of reproductive potential should use effective contraception during treatment with BESPONSA and for at least 5 months after the last dose Are breastfeeding or plan to breastfeed. Avoid breastfeeding during treatment with BESPONSA and for at least 2 months after the final dose. When considering the use of BESPONSA as a treatment for relapsed or refractory B cell ALL, baseline CD22 positivity of > 0% using a validated and sensitive assay is required prior to initiating treatment (see section 5.1).. Learn about the risks & benefits of BESPONSA™, an Rx treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.. Drug Information on Besponsa (inotuzumab ozogamicin) includes drug pictures, side effects, drug interactions, directions for use, symptoms of overdose, and what to avoid.. inotuzumab ozogamicin (BESPONSA®) is accepted for restricted use within NHSScotland. Indication under review: as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL)..
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню